A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen or two different epitopes on the same antigen.[1] Naturally occurring antibodies typically only target one antigen. BsAbs can be manufactured in several structural formats. BsAbs can be designed to recruit and activate immune cells, to interfere with receptor signaling and inactivate signaling ligands, and to force association of protein complexes.[2] BsAbs have been explored for cancer immunotherapy, drug delivery, and Alzheimer's disease.[1][3]
^ abMa J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, et al. (2021). "Bispecific Antibodies: From Research to Clinical Application". Frontiers in Immunology. 12: 626616. doi:10.3389/fimmu.2021.626616. PMC 8131538. PMID 34025638.
^Cite error: The named reference :6 was invoked but never defined (see the help page).
^Fan G, Wang Z, Hao M, Li J (December 2015). "Bispecific antibodies and their applications". Journal of Hematology & Oncology. 8: 130. doi:10.1186/s13045-015-0227-0. PMC 4687327. PMID 26692321.
and 24 Related for: Bispecific monoclonal antibody information
cell lineages. Bispecificmonoclonalantibodies can also be engineered, by increasing the therapeutic targets of one monoclonalantibody to two epitopes...
A bispecificmonoclonalantibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen or two different...
nomenclature of monoclonalantibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonalantibodies. An antibody is a protein...
Monoclonalantibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target,...
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecificmonoclonalantibody for the treatment of haemophilia A, developed by Genentech and...
trifunctional antibody is a monoclonalantibody with binding sites for two different antigens, typically CD3 and a tumor antigen, making it a type of bispecific monoclonal...
encodes an antibody of a different isotype. An antibody can be called monospecific if it has specificity for a single antigen or epitope, or bispecific if it...
(nAMD) and diabetic macular edema (DME). Faricimab is the first bispecificmonoclonalantibody to target both vascular endothelial growth factor (VEGF) and...
brand name Rybrevant, is a bispecificmonoclonalantibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF)...
brand name Columvi, is a bispecificmonoclonalantibody used for the treatment of large B-cell lymphoma. It is a bispecific CD20-directed CD3 T-cell engager...
obtaining a bispecificantibody (with both Fab and Fcab regions containing distinct binding sites). These bispecificmonoclonalantibodies are sometimes...
Solitomab (INN; development code MT110) is an artificial bispecificmonoclonalantibody that is being investigated as an anti-cancer drug. It is a fusion...
Cadonilimab is a PD-1/CTLA-4 bispecificmonoclonalantibody developed to treat a variety of solid cancer types. In June 2022 it was approved in China "for...
humanized monoclonalantibody used for the treatment of multiple myeloma. It is a bispecific GPRC5D-directed CD3 T-cell engager. Talquetamab is a bispecific antibody...
under the brand name Lunsumio, is a monoclonalantibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells...
urine tests finding abnormal antibody proteins - (often using electrophoretic techniques revealing the presence of a monoclonal spike in the results - termed...
Odronextamab (REGN1979) is a CD20 x CD3 bispecificmonoclonalantibody that is developed by Regeneron Pharmaceuticals for B-cell non-Hodgkin lymphoma....
Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonalantibody designed for the treatment of cancer. It acts as an immunomodulator and binds to...
Epkinly, is a monoclonalantibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed...
Istiratumab (MM-141) is an experimental monoclonalantibody for the treatment of cancer. It is a bispecificantibody targeting IGF-1R and ErbB3. It is in...
Catumaxomab (trade name Removab) is a rat-mouse hybrid monoclonalantibody which is used to treat malignant ascites, a condition occurring in people with...
is an experimental non-opioid analgesic drug that works as a bispecificmonoclonalantibody against tumour necrosis factor (TNF) and nerve growth factor...
Global Information